Identification
- Composition (DCI)
- agalsidase bêta
- Manufacturer
- SANOFI AVENTIS MAROC
- ATC code
- A16AB04
- Presentation
- Boite de 1 flacon de 20 ml
- Schedule / Reimb.
- A
- Hospital price
- 34798.00 MAD
Indications
Traitement enzymatique substitutif chez les patients atteints de la maladie de Fabry (déficit en α-galactosidase A). Les données concernant l’efficacité et la sécurité ont été évaluées pour une durée de traitement allant jusqu’à 18 mois.
Find an open pharmacy
On-call pharmacies near you
About FABRAZYME 35 MG
FABRAZYME 35 MG is marketed in Morocco by SANOFI AVENTIS MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of FABRAZYME 35 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about FABRAZYME 35 MG
Answers to common questions from Moroccan patients about this drug.